Literature DB >> 2015664

Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis.

B J Oberhardt1, S C Dermott, M Taylor, Z Y Alkadi, A F Abruzzini, N J Gresalfi.   

Abstract

Rapid coagulation and fibrinolysis assays suitable for use with an imprecisely measured sample volume (either whole blood or plasma) have been developed, utilizing a technology based on paramagnetic iron oxide particles (PIOP) that move in response to an oscillating magnetic field. PIOP are combined with appropriate test reagents for clotting and thrombolysis assays and formulated as dry reagents within a capillary test chamber. The minima and maxima of the PIOP oscillations define a two-sided waveform that provides kinetic information on fibrin polymerization and lysis. Subject to the chemistry of the dry reagent formulation, the resulting waveform can be used to define clotting time, lysis onset time, or fibrinogen variables. Applications to one-stage prothrombin time and one-stage activated partial thromboplastin time tests have yielded assays with consistently good correlations with other test methods. Applications to fibrinolysis studies have yielded global assays of thrombolytic activity, in that the assay results reflect the interactions of multiple factors associated with the effectiveness of thrombolytic therapy. Depending on the components utilized in a particular reagent formulation, one can derive information about the activity of such factors as fibrinogen, plasminogen, and related inhibitors, as well as the lytic agent being administered. Use of these assays in a clinical setting should provide a rapid, convenient alternative to conventional testing of coagulation variables and a reliable method for monitoring thrombolytic therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015664

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  10 in total

1.  Recommendations for patients undertaking self management of oral anticoagulation.

Authors:  D A Fitzmaurice; S J Machin
Journal:  BMJ       Date:  2001-10-27

Review 2.  Anticoagulation in patients with thromboembolic disease.

Authors:  R C Tait
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 3.  Oral anticoagulation control: the European perspective.

Authors:  David A Fitzmaurice
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

4.  Where should oral anticoagulation monitoring take place?

Authors:  F D Hobbs; D A Fitzmaurice
Journal:  Br J Gen Pract       Date:  1997-08       Impact factor: 5.386

5.  Monitoring oral anticoagulant treatment with the TAS near-patient test system: comparison with conventional thromboplastins.

Authors:  S Kitchen; F E Preston
Journal:  J Clin Pathol       Date:  1997-11       Impact factor: 3.411

6.  A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management.

Authors:  D A Fitzmaurice; E T Murray; K M Gee; T F Allan; F D R Hobbs
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

7.  Two monitoring methods of oral anticoagulant therapy in patients with mechanical heart valve prothesis: a meta-analysis.

Authors:  Zhe Xu; Zhiping Wang; Jingsong Ou; Yingqi Xu; Song Yang; Xi Zhang
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

8.  Advances in the Monitoring of Oral Anticoagulation: Point-of-Care Testing, Patient Self-Monitoring, and Patient Self-Management.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 9.  Home monitoring of anticoagulation.

Authors:  Julie Hambleton
Journal:  J Thromb Thrombolysis       Date:  2003 Aug-Oct       Impact factor: 2.300

10.  SMART: self-management of anticoagulation, a randomised trial [ISRCTN19313375].

Authors:  Deborah McCahon; David A Fitzmaurice; Ellen T Murray; Christopher J Fuller; Richard F D Hobbs; Teresa F Allan; James P Raftery
Journal:  BMC Fam Pract       Date:  2003-09-18       Impact factor: 2.497

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.